Advertisement
Canada markets close in 5 hours 17 minutes
  • S&P/TSX

    22,173.11
    +66.03 (+0.30%)
     
  • S&P 500

    5,252.72
    +4.23 (+0.08%)
     
  • DOW

    39,741.95
    -18.13 (-0.05%)
     
  • CAD/USD

    0.7378
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    82.30
    +0.95 (+1.17%)
     
  • Bitcoin CAD

    96,637.23
    +1,609.30 (+1.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,229.30
    +16.60 (+0.75%)
     
  • RUSSELL 2000

    2,122.38
    +8.03 (+0.38%)
     
  • 10-Yr Bond

    4.2020
    +0.0060 (+0.14%)
     
  • NASDAQ

    16,403.42
    +3.90 (+0.02%)
     
  • VOLATILITY

    13.03
    +0.25 (+1.95%)
     
  • FTSE

    7,960.29
    +28.31 (+0.36%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6823
    +0.0018 (+0.26%)
     

Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session

Aeglea BioTherapeutics, Inc. AGLE was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $6.51 – $7.38 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Aeglea currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

 

Aeglea BioTherapeutics, Inc. Price

Aeglea BioTherapeutics, Inc. Price
Aeglea BioTherapeutics, Inc. Price

Aeglea BioTherapeutics, Inc. price | Aeglea BioTherapeutics, Inc. Quote

ADVERTISEMENT

 

A better-ranked stock in the Medical sector is AVEO Pharmaceuticals Inc AVEO, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AVEO Pharmaceuticals, Inc. (AVEO) : Free Stock Analysis Report
 
Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research